8,700 Studies Reviewed. 87.0% Found Biological Effects. The Evidence is Clear.
Shield Your Body
Cancer & Tumors1,292 citations

Kumar S, Behari J, Sisodia R

Bioeffects Seen

Authors not listed · 2013

Share:

Multiple myeloma survival improved dramatically from 2006-2010, highlighting the importance of both better treatments and cancer prevention strategies.

Plain English Summary

Summary written for general audiences

This study tracked 1,038 multiple myeloma patients from 2001-2010, comparing survival rates between two time periods. Patients diagnosed in 2006-2010 lived significantly longer (6.1 years median survival) compared to those diagnosed in 2001-2005 (4.6 years), with the greatest improvements seen in patients over 65.

Why This Matters

While this study focuses on cancer treatment outcomes rather than EMF exposure, it provides important context for understanding multiple myeloma survival trends. The science demonstrates that multiple myeloma remains a serious blood cancer, though treatment advances have improved outcomes significantly over the past decade. What this means for you is that any environmental factors potentially linked to multiple myeloma development deserve serious attention. Some research has suggested possible connections between EMF exposure and blood cancers, though the evidence remains limited. The reality is that while we celebrate these treatment improvements, prevention remains the best medicine. Put simply, reducing unnecessary EMF exposure represents a precautionary approach that costs nothing but could potentially reduce cancer risk.

Exposure Information

Specific exposure levels were not quantified in this study.

Cite This Study
Unknown (2013). Kumar S, Behari J, Sisodia R.
Show BibTeX
@article{kumar_s_behari_j_sisodia_r_ce3755,
  author = {Unknown},
  title = {Kumar S, Behari J, Sisodia R},
  year = {2013},
  doi = {10.1038/leu.2013.313},
  
}
DOI: 10.1038/leu.2013.313PubMed: 24157580

Quick Questions About This Study

Median survival increased from 4.6 years for patients diagnosed in 2001-2005 to 6.1 years for those diagnosed in 2006-2010, representing a 33% improvement in survival time.
Patients over 65 experienced the most dramatic improvement, with 6-year survival rates jumping from 31% to 56% between the two time periods studied.
Yes, first-year mortality dropped significantly from 16% in 2001-2005 to just 10% in 2006-2010, indicating better early treatment outcomes and reduced immediate complications.
The improvements were directly linked to using one or more new therapeutic agents in initial treatment, representing a major advancement in multiple myeloma care protocols.
Of the 1,038 patients studied over nearly 6 years of follow-up, 47% remained alive at the last follow-up, demonstrating the serious nature of this blood cancer.